AC
CCCC icon

Athanor Capital’s C4 Therapeutics CCCC Stock Holding History

Athanor Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,132
Closed -$375K – 488
2021
Q1 		$375K Buy
10,132
+3,647
+56% +$145K 0.01% 540
2020
Q4 		$215K Buy
+6,485
New +$188K ﹤0.01% 646

Other funds holding CCCC

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Athanor Capital's CCCC Position: Q2 2021 in Review

Athanor Capital sold out of C4 Therapeutics (CCCC) in Q2 2021, closing a stake of 10,132 shares — an estimated $375K sold.

Athanor Capital first reported a position in CCCC in Q4 2020 and held it in 2 quarters. The position peaked at $375K in Q1 2021. 107 funds tracked by Wall St. Rank hold CCCC as of Q2 2021.

  • Athanor Capital reported no remaining C4 Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 10,132 C4 Therapeutics shares in Q2 2021, an estimated $375K.
  • Athanor Capital first reported a position in C4 Therapeutics in Q4 2020 and held it in 2 quarters.
  • Athanor Capital's C4 Therapeutics position peaked at $375K in Q1 2021.
  • 107 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.